Literature DB >> 3399296

Live virus vaccines in human immunodeficiency virus-infected children: a retrospective survey.

M McLaughlin1, P Thomas, I Onorato, A Rubinstein, J Oleske, S Nicholas, K Krasinski, P Guigli, W Orenstein.   

Abstract

Live virus vaccines can cause serious adverse reactions when administered to immunocompromised patients. Because children infected with human immunodeficiency virus (HIV) may be immunosuppressed, immunization of these children with live virus vaccines is a potential problem. A retrospective survey was conducted by the New York City Department of Health, with consultation from the Centers for Disease Control, to evaluate the frequency of serious adverse events following receipt of live vaccines among children with HIV infection receiving pediatric care in New York City and New Jersey. Outpatient records of 319 children being cared for by 16 participating physicians were reviewed. Of the 319 charts, 221 (69%) contained vaccination histories. Perinatal transmission of HIV infection was suspected for 208 (94%) of the 221 cases and infection via transfusion for the remaining 13 (6%). Of the 221 for whom immunization histories were available, 180 (81%) had received at least one dose of live oral polio vaccine and 70 (32%) had received measles, mumps, and rubella vaccine. There were 120 children for whom a temporal relationship between immunization and onset of symptoms of immunodeficiency could be seen; 46/120 had received at least one dose of oral polio vaccine and 23/45 had received measles, mumps, and rubella vaccine after onset of symptoms. Although follow-up of this population has been limited, there were no reports of serious adverse events such as typical or atypical measles, paralytic poliomyelitis, or aseptic meningitis in the month following vaccination.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3399296

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

1.  Measles vaccination: Weighing the benefits and risks of a live viral vaccine for HIV-infected children.

Authors: 
Journal:  Can J Infect Dis       Date:  1996-07

Review 2.  Immunization of HIV infected children.

Authors:  Jagdish Chandra; Dinesh Yadav
Journal:  Indian J Pediatr       Date:  2012-02-10       Impact factor: 1.967

3.  Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers.

Authors:  M Barbi; M Bardare; C Luraschi; G Zehender; M Clerici Schoeller; G Ferraris
Journal:  Eur J Epidemiol       Date:  1992-03       Impact factor: 8.082

4.  Paralytic poliomyelitis associated with live oral poliomyelitis vaccine in child with HIV infection in Zimbabwe: case report.

Authors:  I Chitsike; R van Furth
Journal:  BMJ       Date:  1999-03-27

5.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

Review 6.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 7.  Routine immunization of the HIV-positive asymptomatic patient.

Authors:  G A Poland; K R Love; C E Hughes
Journal:  J Gen Intern Med       Date:  1990 Mar-Apr       Impact factor: 5.128

Review 8.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

9.  Preventing secondary infections among HIV-positive persons.

Authors:  G A Filice; C Pomeroy
Journal:  Public Health Rep       Date:  1991 Sep-Oct       Impact factor: 2.792

10.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.